Perform Another (Advanced) Search

1.  Study Posting (2205) Trial #156860, Breast Cancer, Chicago, IL
...Study Posting (2205) Trial #156860, Breast Cancer, Chicago, IL Trial Information The Impact of Intestinal Bacteria on Breast Cancer The purpose of this study is to find out the types of bacteria that normally live in your large intestine and their metabolic activity (i.e. the ways ...
View Page

2.  Study Posting (2205) Trial #156842, Ulcerative Colitis, Chicago, IL
...Information Dysbiosis in inflammatory bowel disease. The purpose of this research is to investigate the bacteria that lives in the intestines and colon of healthy individuals compared to persons experiencing IBD. Humans have bacteria that live and grow in the colon. These bacteria serve important purposes in the colon ...
View Page

3.  Study Posting (2205) Trial #156841, Crohn's Disease, Chicago, IL
...Information Dysbiosis in inflammatory bowel disease. The purpose of this research is to investigate the bacteria that lives in the intestines and colon of healthy individuals compared to persons experiencing IBD. Humans have bacteria that live and grow in the colon. These bacteria serve important purposes in the colon ...
View Page

4.  Study Posting (2205) Trial #156840, Inflammatory Bowel Disease, Chicago, IL
...Information Dysbiosis in inflammatory bowel disease. The purpose of this research is to investigate the bacteria that lives in the intestines and colon of healthy individuals compared to persons experiencing IBD. Humans have bacteria that live and grow in the colon. These bacteria serve important purposes in the colon ...
View Page

5.  Study Posting (5359) Trial #155051, Urinary Tract Infections, West Reading, PA
...with the diagnosis of Complicated Urinary Tract Infection or Acute Pyelonephritis caused by gram negative bacteria. If so, please contact Crystal Nagle at 610-988-4308 and see if this study ...
...NXL/2001 to treat Complicated Urinary Tract Infections or Acute Pyelonephritis caused by gram negative bacteria. Patient Inclusion Criteria: • Patients 18-90 years of age. • Diagnosis of a Complicated Urinary Tract ...
View Page

6.  Study Posting (96) Trial #160056, Psoriasis and Psoriatic Disorders, New York, NY
...be an inherited disease. The study is being done to answer basic biological questions regarding bacteria harmlessly growing on the skin. We would like to test skin scales for bacterial growth and see if we can eliminate this bacteria in the laboratory. Skin scales are excess dead skin cells that are produced because of ...
View Page

7.  Study Posting (1570) Trial #156494, Cystic Fibrosis, Morristown, NJ
...chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the ...
...treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial ...
View Page

8.  Newly Approved Drug Therapies (353) Omnicef, Warner-Lambert,
...conference presentations. Drug Name: Omnicef Company: Warner-Lambert Approval Status: Approved December 1997 Treatment Area: bacteria causing pulmonary, throat, and skin infections General Information Omnicef (cefdinir), a broad spectrum antibiotic for ...
View Page

9.  Newly Approved Drug Therapies (597) Tequin, Bristol-Myers Squibb,
...this is a solution of gatifloxacin indicated for community-acquired respiratory tract infections and certain bacteria-caused sexually transmitted diseases. It was created with a unique 8-methoxy structure that seems ...
...to increase bactericidal action and lessen the rate of growth of resistance of gram-positive bacteria. Therefore, it can treat some infections that other antibiotics like penicillin cannot. There were estimated ...
View Page

10.  Newly Approved Drug Therapies (94) Bactroban Nasal 2% (mupirocin calcium ointment), SmithKline Beecham,
...2% (mupirocin calcium ointment) Company: SmithKline Beecham Approval Status: Approved April 1996 Treatment Area: nasal bacteria General Information Bactroban Nasal has been approved as an intranasally administered topical agent for the ...
...free of S. aureus at the end of therapy (five days) remained free of the bacteria four weeks after treatment compared with 12.5% of the placebo volunteers. No serious side ...
View Page

11.  Newly Approved Drug Therapies (657) Clindamycin phosphate topical gel, Target Research Associates,
...acne vulgaris. This drug belongs to the class of antibiotics known as lincosamides. By inhibiting bacteria protein synthesis at the ribosomal level (the site of protein synthesis), clindamycin is believed to kill bacteria associated with acne. The term "acne vulgaris" refers to the more common form of acne ...
View Page

12.  Newly Approved Drug Therapies (1028) Besivance (besifloxacin ophthalmic suspension), Bausch & Lomb,
...General Information Besivance is a fluoroquinolone antibacterial with activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is ...
...specifically indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: • Corynebacterium pseudodiphtheriticum • Corynebacterium striatum Haemophilus influenzae • Moraxella lacunata • Staphylococcus aureus • Staphylococcus epidermidis • Staphylococcus hominis • Staphylococcus ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (177), Skin Infections/Disorders
...randomized, double-blind, dose-ranging study enrolled 188 subjects with cSSSI caused by gram-positive bacteria. Torezolid was administered orally at doses of 200, 300 or 400 mg once-daily for ...
...II, enrolled 1,396 adult subjects with cSSSI caused by gram-positive and gram-negative bacteria. The primary endpoint was non-inferiority of ceftaroline compared to vancomycin plus aztreonam, with a ...
View Page

14.  Newly Approved Drug Therapies (19) Cedax (ceftibuten), Schering-Plough,
...General Information Clinical studies have demonstrated that Cedax is active against a broad spectrum of bacteria that are common causes of upper and lower respiratory tract infections. These include most strains ...
...Streptococcus pyogenes. Cedax is highly stable in the presence of beta-lactamases--enzymes produced by bacteria that can render some commonly used antibiotics, such as amoxicillin or penicillin, ineffective. Side Effects ...
View Page

15.  Newly Approved Drug Therapies (88) Prilosec (omeprazole)/Biaxin (clarithromycin) Combination Therapy, Astra Merck, Abbott Laboratories,
...treatment of subjects with H. pylori infection and duodenal ulcer to eradicate H. pylori, the bacteria now believed to cause approximately 90% of peptic ulcers. H. pylori eradication has been shown ...
...against these powerful substances resulted in ulcers. However, researchers now know that the H. pylori bacteria (along with acid secretion) damages stomach and duodenal tissue, causing inflammation and ulcers in 90% ...
View Page

16.  Newly Approved Drug Therapies (231) Klaron (sodium sulfacet amide lotion ) Lotion, 10%, Dermik Laboratories,
...surface of the skin, when oil glands (sebaceous glands) become clogged by skin cells and bacteria that block the opening of the pores. If the blocked pore is closed, it forms ...
...if the pore is open it forms a blackhead. Red, inflamed pimples appear when the bacteria breaks through the wall of the whitehead or blackhead. Acne occurs most often on the ...
View Page

17.  Study Posting (77) Trial #156088, Staphylococcal Infections, New Hyde Park, NY
...by Schneider Children’s Hospital for the Prevention of Staphylococcal Sepsis ("staph" infection caused by bacteria). An infant may be eligible to participate in this study if s/he: • Is an ...
View Page

18.  Study Posting (77) Trial #156450, Staphylococcal Infections, Manhasset, NY
...s Hospital at North Shore for the Prevention of Staphylococcal Sepsis ("staph" infection caused by bacteria) An infant may be eligible to participate in this study if s/he: • Is an ...
View Page

19.  CenterWatch: New Medical Therapies in Disease Category (799), Staphylococcal Skin Infections
...randomized, double-blind, dose-ranging study enrolled 188 subjects with cSSSI caused by gram-positive bacteria. Torezolid was administered orally at doses of 200, 300 or 400 mg once-daily for ...
...II, enrolled 1,396 adult subjects with cSSSI caused by gram-positive and gram-negative bacteria. The primary endpoint was non-inferiority of ceftaroline compared to vancomycin plus aztreonam, with a ...
View Page

20.  Newly Approved Drug Therapies (43) Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed), Connaught Laboratories,
...and difficulty in breathing. Tripedia is made of just a portion of the killed pertussis bacteria. This acellular vaccine has also been approved in the United States for booster shots in ...
...infants be immunized against whooping cough with a vaccine made of the entire killed pertussis bacteria. Very rarely does the vaccine cause brain damage. While the vast majority of the side ...
View Page